ICL670 + Chelation + No chelation

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Aplastic Anemia

Conditions

Aplastic Anemia

Trial Timeline

Jun 23, 2014 → Oct 17, 2016

About ICL670 + Chelation + No chelation

ICL670 + Chelation + No chelation is a approved stage product being developed by Novartis for Aplastic Anemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01818726. Target conditions include Aplastic Anemia.

What happened to similar drugs?

0 of 6 similar drugs in Aplastic Anemia were approved

Approved (0) Terminated (1) Active (5)
🔄Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
🔄hATG + CsA + EltrombopagNovartisPhase 3
🔄Alectinib + CrizotinibRochePhase 3
🔄PF-06462700PfizerPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01818726ApprovedTerminated

Competing Products

20 competing products in Aplastic Anemia

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
AlefaceptAstellas PharmaPhase 1
21
RomiplostimKyowa KirinPhase 2/3
38
Lenvatinib 24 mgEisaiPhase 2
27
RomiplostimKyowa KirinPhase 2/3
38
RomiplostimKyowa KirinPhase 2/3
38
AMG531Kyowa KirinPhase 2
35
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
39
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
44
Trappa ethanolamine tablets ; ciclosporin + Placebo ; ciclosporinJiangsu Hengrui MedicinePhase 2
31
Hetrombopag Olamine Tablet;Ciclosporin Soft CapsuleJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
29
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1/2
32
Hetrombopag Olamine+Standard Therapy + Placebo+Standard TherapyJiangsu Hengrui MedicinePhase 3
40
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
PosaconazoleMerckPhase 2
35
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension CohortNovartisPhase 1/2
36